Skip to content
2000
Volume 13, Issue 3
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

This review presents a concise update on the inhibitors of the neuroenzyme, acetylcholinesterase (AChE; EC 3.1.1.7). AChE is a serine protease, which hydrolyses the neurotransmitter, acetylcholine into acetate and choline thereby terminating neurotransmission. Molecular interactions (mode of binding to the target enzyme), clinical applications and limitations have been summarized for each of the inhibitors discussed. Traditional inhibitors (e.g. physostigmine, tacrine, donepezil, rivastigmine etc.) as well as novel inhibitors like various physostigmine-derivatives have been covered. This is followed by a short glimpse on inhibitors derived from nature (e.g. Huperzine A and B, Galangin). Also, a discussion on ‘hybrid of pre-existing drugs’ has been incorporated. Furthermore, current status of therapeutic applications of AChEinhibitors has also been summarized.

Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/18715273113126660166
2014-04-01
2025-09-10
Loading full text...

Full text loading...

/content/journals/cnsnddt/10.2174/18715273113126660166
Loading

  • Article Type:
    Research Article
Keyword(s): acetylcholine; Acetylcholinesterase; huperzine A; physostigmine; rivastigmine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test